ELOI FENEL M 4

What Happened Eloi Fenel, a director of Standard BioTools, was granted two compensation awards on June 18, 2026: 99,116 restricted stock units (RSUs) and 175,923 derivative awards (reported as a derivative acquisition). Both awards were reported at $0.00 (no cash paid at grant).

Key Details

• Transaction date: 2026-06-18; Form 4 filed 2026-06-23 (filed after the typical two-business-day deadline for Form 4s).
• Award amounts and values: 99,116 RSUs @ $0.00 (Acquired) and 175,923 derivative award units @ $0.00 (Acquired); reported dollar value $0 for both.
• Vesting / exercisability (per footnotes):
  • F1: The 99,116 RSUs convert to one share each and vest in full on the earlier of June 18, 2027 or one day before the next annual meeting, subject to continued service.
  • F2: The derivative award (option) becomes exercisable in 12 equal monthly installments beginning July 18, 2026, subject to continued service.
• Shares owned after transaction: not specified in the provided filing excerpt.
• No indication of a 10b5-1 plan, sale, tax withholding sale, or cashless exercise in the disclosed items.

Context These entries are compensation awards (RSUs and an option-like derivative) rather than purchases or open-market sales. Awards are common for directors and reflect compensation/retention mechanics; they do not by themselves indicate a buy or sell signal. Note the filing date is several days after the grant date, which is later than the usual two-business-day Form 4 deadline.